TW200504079A - Crystallization and purification of macrolides - Google Patents

Crystallization and purification of macrolides

Info

Publication number
TW200504079A
TW200504079A TW093108933A TW93108933A TW200504079A TW 200504079 A TW200504079 A TW 200504079A TW 093108933 A TW093108933 A TW 093108933A TW 93108933 A TW93108933 A TW 93108933A TW 200504079 A TW200504079 A TW 200504079A
Authority
TW
Taiwan
Prior art keywords
crystallization
purification
macrolides
macrolide
dopolar
Prior art date
Application number
TW093108933A
Other languages
English (en)
Inventor
Vilmos Keri
Andrea Csorvasi
Original Assignee
Biogal Gyogyszergyar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogal Gyogyszergyar filed Critical Biogal Gyogyszergyar
Publication of TW200504079A publication Critical patent/TW200504079A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
TW093108933A 2003-03-31 2004-03-31 Crystallization and purification of macrolides TW200504079A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45959103P 2003-03-31 2003-03-31
US46170703P 2003-04-09 2003-04-09
US51288703P 2003-10-20 2003-10-20

Publications (1)

Publication Number Publication Date
TW200504079A true TW200504079A (en) 2005-02-01

Family

ID=33162981

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093108933A TW200504079A (en) 2003-03-31 2004-03-31 Crystallization and purification of macrolides

Country Status (10)

Country Link
US (1) US7232486B2 (zh)
EP (1) EP1513847A2 (zh)
JP (1) JP4468943B2 (zh)
KR (1) KR20050114262A (zh)
DE (1) DE04758730T1 (zh)
ES (1) ES2229975T1 (zh)
IL (1) IL170331A (zh)
TR (1) TR200500302T3 (zh)
TW (1) TW200504079A (zh)
WO (1) WO2004089958A2 (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306166B1 (en) * 1997-08-13 2001-10-23 Scimed Life Systems, Inc. Loading and release of water-insoluble drugs
JP2007519757A (ja) * 2004-12-01 2007-07-19 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ ピメクロリマスの調製方法
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
KR100859670B1 (ko) 2006-09-13 2008-09-23 동국제약 주식회사 타크로리무스를 고수율 및 고순도로 정제하는 방법
CA2668134A1 (en) * 2006-11-06 2008-05-15 Teva Gyogyszergyar Zartkoerueen Muekoedoe Reszvenytarsasag Ascomycin and pimecrolimus having reduced levels of des-methylascomycin and 32-deoxy-32-epichloro-desmethylascomycin respectively, and methods for preparation thereof
US20100029933A1 (en) * 2006-11-10 2010-02-04 Biocon Limited Pure form of rapamycin and a process for recovery and purification thereof
NZ588816A (en) 2007-01-21 2011-11-25 Hemoteq Ag Medical device for the treatment of stenoses of corporal lumina and for the prevention of impending restenoses
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
JP5643770B2 (ja) * 2009-01-21 2014-12-17 バイオコン・リミテッドＢｉｏｃｏｎ Ｌｉｍｉｔｅｄ シロリムスの安定性の決定方法およびその安定形態の調製方法
WO2011005421A2 (en) 2009-07-10 2011-01-13 Boston Scientific Scimed, Inc. Use of nanocrystals for a drug delivery balloon
JP5933434B2 (ja) 2009-07-17 2016-06-08 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 薬剤送達バルーンの製造方法
US20110160645A1 (en) * 2009-12-31 2011-06-30 Boston Scientific Scimed, Inc. Cryo Activated Drug Delivery and Cutting Balloons
US8889211B2 (en) 2010-09-02 2014-11-18 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
WO2013022458A1 (en) 2011-08-05 2013-02-14 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
US9056152B2 (en) 2011-08-25 2015-06-16 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
CN103159812B (zh) * 2011-12-08 2016-03-23 湖南中创化工股份有限公司 一种从红霉素水溶液中提取红霉素的方法
WO2014072984A1 (en) 2012-11-06 2014-05-15 Natco Pharma Limited Improved process for isolation and purification of rapamycin from fermentation broth
CN102942607A (zh) * 2012-11-28 2013-02-27 宁夏启元药业有限公司 一种复合溶剂结晶红霉素的方法
CN108864149B (zh) 2013-03-15 2022-04-05 生物传感器国际集团有限公司 雷帕霉素衍生物的纯化
US9439892B2 (en) 2013-05-16 2016-09-13 Surmodics, Inc. Macrolide particulates, methods for preparation, and medical devices associated therewith
EP3007679B1 (en) 2013-06-12 2020-11-11 SurModics, Inc. Solvent methods for preparing crystalline macrolide particulates, compositions, and articles containing particulates
EP3435988B1 (en) 2016-03-31 2021-10-06 Surmodics, Inc. Drug-containing particulate composition with cationic agent, associated medical devices, and methods for treatment
EP3554571A1 (en) 2016-12-16 2019-10-23 Surmodics, Inc. Hydrophobic active agent particle coatings and methods for treatment

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1666924A (en) 1924-06-23 1928-04-24 John J Selb Arch support
DE2121517C3 (de) 1971-04-30 1974-06-27 Leningradskij Nautschno-Issledowatelskij Institut Antibiotikow, Ssr, Leningrad (Sowjetunion) Verfahren zur Gewinnung von Amphoterizin B
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4160861A (en) 1977-10-03 1979-07-10 Merck & Co., Inc. Method for the separation of antibiotic macrolides
US4543334A (en) * 1983-12-16 1985-09-24 Pfizer Inc. Streptomyces capable of producing neutral macrolide antibacterial agents
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
JPH0216662A (ja) * 1988-07-05 1990-01-19 Nec Corp 代替端末コントロール装置
JP2639737B2 (ja) 1990-01-23 1997-08-13 寳酒造株式会社 新規ｒ１０６類化合物
US5116756A (en) 1991-01-28 1992-05-26 Merck & Co., Inc. Process for producing FK-506
EP0582690A1 (en) 1991-04-11 1994-02-16 Pfizer Inc. Novel immunosuppressant agent from streptomyces braegensis
US5091389A (en) 1991-04-23 1992-02-25 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
JPH07500613A (ja) 1992-03-02 1995-01-19 ファイザー・インコーポレーテッド 免疫抑制剤及び抗真菌剤としてのマクロライドのデソサミノ誘導体
UA41884C2 (uk) * 1993-11-05 2001-10-15 Амерікан Хоум Продактс Корпорейшн Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів
US5622866A (en) 1994-06-23 1997-04-22 Merck & Co., Inc. Expression cassettes useful in construction of integrative and replicative expression vectors for Streptomyces
GB9618952D0 (en) 1996-09-11 1996-10-23 Sandoz Ltd Process
GB9826882D0 (en) * 1998-12-07 1999-01-27 Novartis Ag Organic compounds
ES2177373B1 (es) * 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
CZ20022779A3 (cs) 2000-02-24 2003-02-12 Biogal Gyogyszergyar Rt. Způsob purifikace fermentačního bujónu
JP4261365B2 (ja) * 2002-02-13 2009-04-30 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ 生物学的物質からのマクロライドの抽出方法
US7452692B2 (en) * 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter

Also Published As

Publication number Publication date
WO2004089958A2 (en) 2004-10-21
EP1513847A2 (en) 2005-03-16
DE04758730T1 (de) 2005-06-23
ES2229975T1 (es) 2005-05-01
JP4468943B2 (ja) 2010-05-26
WO2004089958B1 (en) 2005-03-03
TR200500302T3 (tr) 2005-04-21
US7232486B2 (en) 2007-06-19
WO2004089958A3 (en) 2005-01-13
US20040226501A1 (en) 2004-11-18
IL170331A (en) 2010-04-15
KR20050114262A (ko) 2005-12-05
JP2006522018A (ja) 2006-09-28

Similar Documents

Publication Publication Date Title
TW200504079A (en) Crystallization and purification of macrolides
IL182872A0 (en) Ascomycin crystalline forms and preparation thereof
WO2003072026A3 (en) Method of reducing and treating uvb-induced immunosuppression
WO2005102943A3 (en) Wastewater treatment
UA84881C2 (ru) Аморфный 42-эфир рапамицина и 3-гидрокси-2-(гидроксиметил)-2-метилпропионовой кислоты и фармацевтическая композиция, содержащая его
WO2006071862A3 (en) Polymorphs of 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate
WO2007041697A3 (en) Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease
IL166640A0 (en) Compounds with the bicyclo Ä4.2.1Ü nonane system for the treatment of flaviviridae infections
HK1093503A1 (en) Pyrido 2, 1-a-isoquinoline derivatives as ddp-IV inhibitors
EP1892125A3 (en) Amine containing catalyst system and methods of use thereof
WO2006098961A3 (en) Fused thieno [2, 3-b] pyridine and thiazolo [5, 4-b] pyridine compounds for inhibiting ksp kinesin activity
WO2005085266A8 (en) Macrocyclic compounds and methods of making and using the same
WO2005044093A3 (en) Delta-9- the treatment of multiple sclerosis
WO2003068980A3 (en) Method for extracting a macrolide from biomatter
WO2005118610A3 (en) Macrocyclic compounds and methods of making and using the same
AU2004262446A1 (en) Method for inhibiting bacterial colonisation
WO2006027691A3 (en) Methods of treating mood disorders using benzisoxazole containing diazabicyclic compounds
AU2283201A (en) Method for helping persons with dyslexia
AU2002311780A1 (en) Methods for isolating genes from microorganisms
WO2005009347A3 (en) 7-substituted camptothecin and camptothecin analogs and methods for preparing same
WO2002085302A3 (en) Methods of treating intestinal inflammation
AU2817000A (en) An educational tool, entertainment system or search tool
EP1654385A4 (en) METHOD FOR ISOLATING AND CLONING HIGH MOLECULAR WEIGHT POLYNUCLEOTIDE MOLECULES FROM THE ENVIRONMENT
TW200517116A (en) Method of treating mantle cell lymphoma
AU2002356005A1 (en) Rpob gene of streptomyces, primer specific to streptomyces, and identification method of streptomyces having rifampin resistance or sensitivity by using the same